Authorized Generics Under Scrutiny By The FTC

Law360, New York (March 31, 2006, 12:00 AM EST) -- With the debate over authorized generics heating up in recent months, this week’s move by the Federal Trade Commission to determine whether the practice violates anticompetitive guidelines could have wide-ranging effects on the pharmaceutical industry, experts say.

Among the largest generic drug makers slated for FTC scrutiny are Andrx Corp. and Teva Pharmaceutical Industries Ltd., both of which have recently been engaged in high-profile battles with brand-name companies over authorized generics.

Teva’s role in the probe may be especially significant in light of the company’s $7.4...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.